SCHEMBL10315372

SCHEMBL10315372

Cc1cc(C)c(N(c2ccc(-c3nnc(-c4ccccc4)o3)cc2)c2ccc(-c3nc4ccccc4nc3-c3ccc(N(c4ccc(-c5nnc(-c6ccccc6)o5)cc4)c4c(C)cc(C)cc4C)cc3)cc2)c(C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.49
RAB9A P51151 10/20 0.49
SMN1; SMN2 Q16637 9/20 0.49
HPGD P15428 6/20 0.49
TDP1 Q9NUW8 2/20 0.49
POLB P06746 2/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
ALDH1A1 P00352 8/20 0.46
TSHR P16473 3/20 0.46
HSD17B10 Q99714 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
KDM4E B2RXH2 5/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
PDE10A Q9Y233 1/20 0.43
MAOB P27338 1/20 0.41
PTGS2 P35354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10315142 1.00 NPC1 (0.49) NPC1RAB9ASMN1; SMN2HPGDTDP1
SCHEMBL10315126 0.90 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HPGDTDP1
SCHEMBL10315145 0.89 NPC1 (0.50) NPC1RAB9ASMN1; SMN2HPGDTDP1
SCHEMBL10315373 0.89 NPC1 (0.50) NPC1RAB9ASMN1; SMN2HPGDTDP1
SCHEMBL10315129 0.88 NPC1 (0.49) NPC1RAB9ASMN1; SMN2HPGDTDP1
SCHEMBL10315370 0.87 RAB9A (0.62) NPC1RAB9ASMN1; SMN2HPGDTDP1
SCHEMBL10315144 0.87 RAB9A (0.62) NPC1RAB9ASMN1; SMN2HPGDTDP1
SCHEMBL10315225 0.87 NPC1 (0.49) NPC1RAB9ASMN1; SMN2HPGDTDP1
SCHEMBL10315121 0.86 RAB9A (0.60) NPC1RAB9ASMN1; SMN2HPGDTDP1
SCHEMBL10315443 0.84 NPC1 (0.47) NPC1RAB9ASMN1; SMN2HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2067778-B1 Quinoxaline derivative, and light emitting element, light emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LAB (JP) 2016-08-17 EP disclosed
US-8216696-B2 Quinoxaline derivative, and light emitting element, light emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-07-10 US disclosed
US-8216696-B2 Quinoxaline derivative, and light emitting element, light emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-07-10 US disclosed
US-20090153041-A1 Quinoxaline Derivative, and Light Emitting Element, Light Emitting Device and Electronic Appliance Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-18 US disclosed
US-20090153041-A1 Quinoxaline Derivative, and Light Emitting Element, Light Emitting Device and Electronic Appliance Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-18 US disclosed
EP-2067778-A1 Quinoxaline derivative, and light emitting element, licht emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090153041-A1 Quinoxaline Derivative, and Light Emitting Element, Light Emitting Device and Electronic Appliance Using the Same SLC1A2, SLC18A2, SLC18A3 NPC1 3369/4885RAB9A 979/4885SMN1; SMN2 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.